RedHill Biopharma Ltd. , a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today reported, following a second pre-planned meeting to assess the safety and efficacy data from its ongoing first Phase III study with RHB-104 for Crohn’s disease (the MAP US study) by an independent Data and Safety Monitoring Board (DSMB), that it has received a unanimous positive recommendation from the DSMB to continue the study as planned.

MEDICAL FAIR THAILAND 2017 will be its largest edition yet, with booth space fully sold out since May, featuring 700 exhibitors from 45 countries including 18 National Pavilions and country groups on a show floor that has expanded by 20% compared to 2015, at the Queen Sirikit National Convention Center. Held biennially, MEDICAL FAIR THAILAND 2017 confirms its position as Thailand’s most prominent trade fair through dynamic sales, wide range of product and services and high-quality line-up of signature conferences and seminars.